Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis

PHASE1TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Myeloma
Interventions
DRUG

Pomalidomide

"Phase I: Starting dose of Pomalidomide 1 mg/day by mouth on days 1-21 of a 28 day cycle.~Phase II: Starting dose of Pomalidomide maximum tolerated dose from Phase I."

DRUG

Melphalan

Phase I and II: 9 mg/m2 by mouth on days 1-4 of a 28-day cycle.

DRUG

Dexamethasone

Phase I and II: 40 mg/day by mouth on days 1-4 of a 28 day cycle.

BEHAVIORAL

Questionnaires

Questionnaires about the feeling in hands and quality of life completed at different time points during the study.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER